image
Healthcare - Medical - Healthcare Information Services - NYSE - US
$ 53.72
0.959 %
$ 10 B
Market Cap
61.75
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one DOCS stock under the worst case scenario is HIDDEN Compared to the current market price of 53.7 USD, Doximity, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one DOCS stock under the base case scenario is HIDDEN Compared to the current market price of 53.7 USD, Doximity, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one DOCS stock under the best case scenario is HIDDEN Compared to the current market price of 53.7 USD, Doximity, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
475 M REVENUE
13.45%
164 M OPERATING INCOME
30.99%
148 M NET INCOME
30.81%
184 M OPERATING CASH FLOW
2.50%
31.2 M INVESTING CASH FLOW
152.04%
-277 M FINANCING CASH FLOW
-271.37%
137 M REVENUE
8.02%
53.1 M OPERATING INCOME
14.89%
44.2 M NET INCOME
6.71%
68.3 M OPERATING CASH FLOW
65.72%
24.2 M INVESTING CASH FLOW
-19.31%
-19.7 M FINANCING CASH FLOW
65.15%
Balance Sheet Doximity, Inc.
image
Current Assets 913 M
Cash & Short-Term Investments 763 M
Receivables 101 M
Other Current Assets 48.7 M
Non-Current Assets 166 M
Long-Term Investments 0
PP&E 24.6 M
Other Non-Current Assets 142 M
Current Liabilities 147 M
Accounts Payable 2.25 M
Short-Term Debt 4.3 M
Other Current Liabilities 141 M
Non-Current Liabilities 30.7 M
Long-Term Debt 12.4 M
Other Non-Current Liabilities 18.3 M
EFFICIENCY
Earnings Waterfall Doximity, Inc.
image
Revenue 475 M
Cost Of Revenue 50.7 M
Gross Profit 425 M
Operating Expenses 261 M
Operating Income 164 M
Other Expenses 16.3 M
Net Income 148 M
RATIOS
89.34% GROSS MARGIN
89.34%
34.47% OPERATING MARGIN
34.47%
31.04% NET MARGIN
31.04%
16.37% ROE
16.37%
13.67% ROA
13.67%
14.45% ROIC
14.45%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Doximity, Inc.
image
Net Income 148 M
Depreciation & Amortization 10.3 M
Capital Expenditures -5.8 M
Stock-Based Compensation 51.1 M
Change in Working Capital -24.5 M
Others -28.6 M
Free Cash Flow 178 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Doximity, Inc.
image
Wall Street analysts predict an average 1-year price target for DOCS of $43.6 , with forecasts ranging from a low of $25 to a high of $70 .
DOCS Lowest Price Target Wall Street Target
25 USD -53.46%
DOCS Average Price Target Wall Street Target
43.6 USD -18.76%
DOCS Highest Price Target Wall Street Target
70 USD 30.31%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Doximity, Inc.
image
Sold
0-3 MONTHS
6.79 M USD 3
3-6 MONTHS
3.67 M USD 4
6-9 MONTHS
1.44 M USD 4
9-12 MONTHS
250 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Nov 12, 2024
Sell 234 K USD
Bryson Anna
Chief Financial Officer
- 4051
57.8313 USD
2 months ago
Nov 12, 2024
Sell 364 K USD
Bryson Anna
Chief Financial Officer
- 6195
58.8169 USD
2 months ago
Nov 12, 2024
Sell 1.18 M USD
Bryson Anna
Chief Financial Officer
- 19754
59.7449 USD
2 months ago
Nov 12, 2024
Sell 4.06 M USD
Bryson Anna
Chief Financial Officer
- 70000
58.0486 USD
2 months ago
Nov 01, 2024
Sell 105 K USD
Wampler Kira Scherer
Director
- 2500
42 USD
2 months ago
Nov 01, 2024
Sell 841 K USD
Cabral Timothy S
Director
- 20000
42.0653 USD
3 months ago
Oct 01, 2024
Sell 109 K USD
Wampler Kira Scherer
Director
- 2500
43.44 USD
4 months ago
Sep 03, 2024
Sell 90.7 K USD
Wampler Kira Scherer
Director
- 2500
36.27 USD
5 months ago
Aug 13, 2024
Sell 237 K USD
Bryson Anna
Chief Financial Officer
- 6685
35.5187 USD
5 months ago
Aug 13, 2024
Sell 262 K USD
Bryson Anna
Chief Financial Officer
- 7367
35.5397 USD
5 months ago
Aug 13, 2024
Sell 277 K USD
Bryson Anna
Chief Financial Officer
- 7633
36.2805 USD
5 months ago
Aug 13, 2024
Sell 302 K USD
Bryson Anna
Chief Financial Officer
- 8315
36.2832 USD
5 months ago
Aug 09, 2024
Sell 1 M USD
Cabral Timothy S
Director
- 30000
33.5 USD
5 months ago
Aug 09, 2024
Sell 186 K USD
Cabral Timothy S
Director
- 5544
33.5 USD
5 months ago
Aug 09, 2024
Sell 1.05 M USD
Bryson Anna
Chief Financial Officer
- 30000
35 USD
5 months ago
Aug 05, 2024
Sell 25.8 K USD
Yang Watkin Phoebe L.
Director
- 1011
25.54 USD
5 months ago
Aug 01, 2024
Sell 70.5 K USD
Wampler Kira Scherer
Director
- 2500
28.182 USD
5 months ago
Jul 29, 2024
Sell 54.7 K USD
Yang Watkin Phoebe L.
Director
- 1940
28.22 USD
6 months ago
Jul 01, 2024
Sell 70 K USD
Wampler Kira Scherer
Director
- 2500
28 USD
7 months ago
Jun 12, 2024
Sell 300 K USD
Cabral Timothy S
Director
- 10000
30 USD
7 months ago
Jun 12, 2024
Sell 450 K USD
Bryson Anna
Chief Financial Officer
- 15000
30.0004 USD
7 months ago
Jun 12, 2024
Sell 450 K USD
Bryson Anna
Chief Financial Officer
- 15000
30 USD
7 months ago
Jun 03, 2024
Sell 70 K USD
Wampler Kira Scherer
Director
- 2500
27.99 USD
8 months ago
May 17, 2024
Sell 68 K USD
Wampler Kira Scherer
Director
- 2500
27.22 USD
8 months ago
May 16, 2024
Sell 35.8 K USD
Overpeck Craig
See Remarks
- 1500
23.85 USD
9 months ago
Apr 01, 2024
Sell 67.4 K USD
Wampler Kira Scherer
Director
- 2500
26.97 USD
10 months ago
Mar 01, 2024
Sell 69.7 K USD
Wampler Kira Scherer
Director
- 2500
27.88 USD
11 months ago
Feb 16, 2024
Sell 45 K USD
Overpeck Craig
See Remarks
- 1500
30.02 USD
11 months ago
Feb 01, 2024
Sell 67.6 K USD
Wampler Kira Scherer
Director
- 2500
27.05 USD
1 year ago
Jan 02, 2024
Sell 141 K USD
Wampler Kira Scherer
Director
- 5000
28.2661 USD
1 year ago
Dec 14, 2023
Sell 65 K USD
Wampler Kira Scherer
Director
- 2500
26 USD
1 year ago
Dec 15, 2023
Sell 66.6 K USD
Wampler Kira Scherer
Director
- 2500
26.65 USD
1 year ago
Nov 24, 2023
Sell 61 K USD
Wampler Kira Scherer
Director
- 2500
24.41 USD
1 year ago
Nov 16, 2023
Sell 37.8 K USD
Overpeck Craig
See Remarks
- 1500
25.23 USD
1 year ago
Oct 16, 2023
Sell 21.6 K USD
Overpeck Craig
See Remarks
- 1000
21.55 USD
1 year ago
Sep 15, 2023
Sell 21.5 K USD
Overpeck Craig
See Remarks
- 1000
21.48 USD
1 year ago
Jul 28, 2023
Sell 165 K USD
Cabral Timothy S
Director
- 4714
34.9569 USD
1 year ago
Jul 12, 2023
Sell 262 K USD
Cabral Timothy S
Director
- 7500
35 USD
1 year ago
Jul 03, 2023
Sell 338 K USD
Cabral Timothy S
Director
- 10000
33.805 USD
1 year ago
Apr 11, 2023
Sell 262 K USD
Cabral Timothy S
Director
- 7500
35 USD
1 year ago
Apr 03, 2023
Sell 320 K USD
Cabral Timothy S
Director
- 10000
31.9955 USD
1 year ago
Feb 14, 2023
Sell 325 K USD
Cabral Timothy S
Director
- 10000
32.5458 USD
1 year ago
Feb 15, 2023
Sell 262 K USD
Cabral Timothy S
Director
- 7500
35 USD
1 year ago
Feb 02, 2023
Sell 1 M USD
Bryson Anna
Chief Financial Officer
- 25000
40 USD
2 years ago
May 27, 2022
Bought 102 K USD
Tangney Schweikert Family Trust
director:
+ 2950
34.5 USD
2 years ago
May 20, 2022
Bought 483 K USD
Jorgensen Paul W.
Chief Revenue Officer
+ 15000
32.1909 USD
2 years ago
May 02, 2022
Sell 19.9 K USD
Wampler Kira Scherer
director:
- 491
40.488 USD
2 years ago
Apr 01, 2022
Sell 106 K USD
Wampler Kira Scherer
director:
- 2000
53.05 USD
2 years ago
Mar 01, 2022
Sell 134 K USD
Wampler Kira Scherer
Director
- 2200
60.7336 USD
2 years ago
Feb 23, 2022
Sell 1.64 M USD
Kliman Gilbert H
Director
- 29174
56.0909 USD
2 years ago
Feb 25, 2022
Sell 48.7 K USD
Kliman Gilbert H
Director
- 826
59 USD
2 years ago
Feb 11, 2022
Sell 34.6 K USD
Wampler Kira Scherer
Director
- 600
57.6667 USD
2 years ago
Feb 11, 2022
Sell 46.5 K USD
Wampler Kira Scherer
Director
- 791
58.7988 USD
2 years ago
Feb 11, 2022
Sell 48.2 K USD
Wampler Kira Scherer
Director
- 809
59.5902 USD
2 years ago
Feb 11, 2022
Sell 220 K USD
Benjamin Regina M.
Director
- 3812
57.6997 USD
2 years ago
Feb 11, 2022
Sell 197 K USD
Benjamin Regina M.
Director
- 3350
58.7427 USD
2 years ago
Feb 11, 2022
Sell 169 K USD
Benjamin Regina M.
Director
- 2838
59.6028 USD
3 years ago
Dec 07, 2021
Sell 561 K USD
Kliman Gilbert H
Director
- 8912
63 USD
3 years ago
Dec 07, 2021
Sell 371 K USD
Kliman Gilbert H
Director
- 5980
62 USD
3 years ago
Dec 03, 2021
Sell 132 K USD
Kliman Gilbert H
director, 10 percent owner:
- 2000
65.8245 USD
3 years ago
Nov 12, 2021
Sell 6.16 M USD
Benjamin Regina M.
Director
- 82500
74.6687 USD
3 years ago
Nov 12, 2021
Sell 1.69 M USD
Benjamin Regina M.
Director
- 22362
75.7034 USD
3 years ago
Nov 12, 2021
Sell 75 K USD
Benjamin Regina M.
Director
- 1000
75.0186 USD
3 years ago
Aug 13, 2021
Sell 1.75 M USD
Bryson Anna
Chief Financial Officer
- 23359
75.001 USD
3 years ago
Aug 13, 2021
Sell 318 K USD
Kleine Joseph B.
Chief Commercial Officer
- 3979
80 USD
3 years ago
Aug 13, 2021
Sell 14.8 M USD
Kleine Joseph B.
Chief Commercial Officer
- 196021
75.689 USD
3 years ago
Jun 28, 2021
Sell 105 M USD
INTERWEST PARTNERS X LP
10 percent owner
- 4289250
24.57 USD
3 years ago
Jun 28, 2021
Bought 20.2 M USD
Spain Kevin
Director
+ 775000
26 USD
3 years ago
Jun 28, 2021
Bought 20.2 M USD
EMERGENCE CAPITAL PARTNERS II LP
10 percent owner
+ 775000
26 USD
3 years ago
Jun 28, 2021
Sell 105 M USD
Kliman Gilbert H
director, 10 percent owner:
- 4289250
24.57 USD
7. News
Stock Picks From Seeking Alpha's December 2024 New Analysts In December, we welcomed 29 new analysts to Seeking Alpha and in this article we are showcasing their stock picks and investment strategies. Five buy picks are highlighted on Viasat, Newmont, NeuroOne Medical, X-Fab Silicon Foundries, and ArcerlorMittal. Analysts' recommendations range from Strong Buy to Strong Sell, covering diverse sectors such as healthcare, technology, energy, and consumer goods. seekingalpha.com - 1 week ago
5 Momentum Stocks to Buy for January After a Tepid December Five stocks have strong momentum for January. These are: DOCS, LUV, ALK, DBX, PARRA. zacks.com - 1 week ago
3 Medical Services Stocks to Buy to Counter Labor Shortage Woes The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. DOCS, BTSG and EMBC are set to gain the most. zacks.com - 2 weeks ago
4 Healthcare Stocks Rising More Than 50% in 2024 With Room to Grow Medical stocks are expected to reap the benefits of affordable health insurance plans, rising surgeries and widespread adoption of telehealth services in the days ahead. However, inflation and supply-chain woes may act as spoilsport. zacks.com - 3 weeks ago
Doximity (DOCS) Ascends But Remains Behind Market: Some Facts to Note Doximity (DOCS) closed the most recent trading day at $58.18, moving +0.61% from the previous trading session. zacks.com - 3 weeks ago
4 MedTech Stocks That Gained More Than 100% in 2024 With Room to Run Here are some strong MedTech stocks - DOCS, CLOV, CLPT and HIMS - that are expected to provide promising gains. zacks.com - 3 weeks ago
This Health Care Software Firm Nears Buy Point After Whopping 101% Year-To-Date Gain Doximity stock jumped over 34% following its most recent earnings report on Nov. 11. Now, shares are nearing a buy point. investors.com - 4 weeks ago
DOXIMITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Doximity, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Doximity, Inc. (NYSE: DOCS) on behalf of long-term stockholders following a class action complaint that was filed against Doximity on April 17, 2024 with a Class Period from February 9, 2022, to April 1, 2024. Our investigation concerns whether the board of directors of Doximity have breached their fiduciary duties to the company. globenewswire.com - 4 weeks ago
Doximity initiated with an Equal Weight at Stephens Stephens initiated coverage of Doximity with an Equal Weight rating and $55 price target. Doximity runs the "leading digital platform for doctors" and is executing on multiple avenues of growth, though it has "settled into a low-to-mid-teens growth profile," the analyst tells investors. The firm believes the current valuation presumes revenue growth will re-accelerate based on the self-serve marketplace increasing up-sell/cross-sell and new product successes and while it sees potential for EBITDA outperformance, the firm lacks "the visibility and conviction to model above-consensus growth and further margin expansion" as a base case, the analyst tells investors. https://thefly.com - 4 weeks ago
Doximity Report Confirms That Telemedicine Serves Key Role in Modern Health Care SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today released its State of Telemedicine Report, showing that 83% of physician telemedicine users surveyed would like virtual care to remain a permanent part of their clinical practice. Among physicians surveyed, 84% highlighted telemedicine's value in improving continuity of care for patients with chronic or complex conditions, and 96% emphasized its role as a complement to. businesswire.com - 1 month ago
Prescription for Profits: 3 Must-Buy Healthcare Stocks Before 2025 The healthcare sector is undergoing significant changes, with technology, innovation and a patient-centric approach as the cornerstones of its growth. zacks.com - 1 month ago
Doximity: Strong Fundamentals And Growth Potential Makes It Attractive Doximity's dominance in digital healthcare is evident with over 80% of U.S. doctors using the platform, driving strong network effects and competitive positioning. The company boasts impressive financials, with earnings surpassing expectations, strong cash reserves, and high margins, indicating robust scalability and efficiency. New AI-powered features and product launches enhance clinical workflows, while leadership's proven track record supports continued market expansion and service broadening. seekingalpha.com - 1 month ago
8. Profile Summary

Doximity, Inc. DOCS

image
COUNTRY US
INDUSTRY Medical - Healthcare Information Services
MARKET CAP $ 10 B
Dividend Yield 0.00%
Description Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Contact 500, 3rd Street, San Francisco, CA, 94107 https://www.doximity.com
IPO Date June 24, 2021
Employees 827
Officers Ms. Jennifer W. Chaloemtiarana J.D. General Counsel & Corporate Secretary Ms. Anna Bryson Chief Financial Officer Mr. Jey Balachandran Chief Technology Officer Mr. Perry Scott Gold Head of Investor Relations Jim Rivas Head of Corporate Communications Ms. Shari Buck Co-founder and SVice President People & Ops Mr. Bruno Miranda Senior Vice President of Engineering Mr. Craig A. Overpeck Senior Vice President of Commercial Operations Mr. Jeffrey A. Tangney Co-Founder, Chief Executive Officer & Chairperson Dr. Nate Gross M.D. Co-Founder & Chief Strategy Officer